← Leaderboards
Jing Fang
University Of South Carolina At Columbia
$1,665,540
Attributed
$1,665,540
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $335.1K · FY2017–21$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,665,540 · 1
By mechanism
R01$1,665,540 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,728,591
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,752,686
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,170,219
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$10,343,043
Research focus
LeukemiaMaintenanceAdaptor Signaling ProteinBindingCell GrowthLoss Of FunctionCell ProliferationBaseCell SurvivalChromosome 5q LossChronicConventional TherapyCell PhysiologyLeukemogenesisDesignDisease ModelFollow-Up StudiesHematologic NeoplasmsHematopoietic Stem CellsIn VitroIn VivoKnock-DownKnock-In MouseMalignant - Descriptor
Grant awards (5)
Targeting the p62 signalosome in leukemia.$335,119
R01 · FY2021 · CA · contact PI
Targeting the p62 signalosome in leukemia.$335,119
R01 · FY2020 · CA · contact PI
Targeting the p62 signalosome in leukemia.$325,064
R01 · FY2019 · CA · contact PI
Targeting the p62 signalosome in leukemia.$335,119
R01 · FY2018 · CA · contact PI
Targeting the p62 signalosome in leukemia.$335,119
R01 · FY2017 · CA · contact PI